Cargando…
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB/RPV). All adults under LAI-CAB/RPV and part of...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413113/ https://www.ncbi.nlm.nih.gov/pubmed/36015214 http://dx.doi.org/10.3390/pharmaceutics14081588 |
_version_ | 1784775656685436928 |
---|---|
author | Thoueille, Paul Alves Saldanha, Susana Schaller, Fabian Munting, Aline Cavassini, Matthias Braun, Dominique Günthard, Huldrych F. Kusejko, Katharina Surial, Bernard Furrer, Hansjakob Rauch, Andri Ustero, Pilar Calmy, Alexandra Stoeckle, Marcel Battegay, Manuel Marzolini, Catia Andre, Pascal Guidi, Monia Buclin, Thierry Decosterd, Laurent A. |
author_facet | Thoueille, Paul Alves Saldanha, Susana Schaller, Fabian Munting, Aline Cavassini, Matthias Braun, Dominique Günthard, Huldrych F. Kusejko, Katharina Surial, Bernard Furrer, Hansjakob Rauch, Andri Ustero, Pilar Calmy, Alexandra Stoeckle, Marcel Battegay, Manuel Marzolini, Catia Andre, Pascal Guidi, Monia Buclin, Thierry Decosterd, Laurent A. |
author_sort | Thoueille, Paul |
collection | PubMed |
description | SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB/RPV). All adults under LAI-CAB/RPV and part of SHCS are enrolled in the project. The study addresses an integrated strategy of treatment monitoring outside the stringent frame of controlled clinical trials, based on relevant patient characteristics, clinical factors, potential drug-drug interactions, and measurement of circulating blood concentrations. So far, 91 blood samples from 46 PLWH have been collected. Most individuals are less than 50 years old, with relatively few comorbidities and comedications. The observed concentrations are globally in accordance with the available values reported in the randomized clinical trials. Yet, low RPV concentrations not exceeding twice the reported protein-adjusted 90% inhibitory concentration have been observed. Data available at present confirm a considerable between-patient variability overall. Based on the growing amount of PK data accumulated during this ongoing study, population pharmacokinetic analysis will characterize individual concentration-time profiles of LAI-CAB/RPV along with their variability in a real-life setting and their association with treatment response and tolerability, thus bringing key data for therapeutic monitoring and precision dosage adjustment of this novel long-acting therapy. |
format | Online Article Text |
id | pubmed-9413113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94131132022-08-27 Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland Thoueille, Paul Alves Saldanha, Susana Schaller, Fabian Munting, Aline Cavassini, Matthias Braun, Dominique Günthard, Huldrych F. Kusejko, Katharina Surial, Bernard Furrer, Hansjakob Rauch, Andri Ustero, Pilar Calmy, Alexandra Stoeckle, Marcel Battegay, Manuel Marzolini, Catia Andre, Pascal Guidi, Monia Buclin, Thierry Decosterd, Laurent A. Pharmaceutics Article SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB/RPV). All adults under LAI-CAB/RPV and part of SHCS are enrolled in the project. The study addresses an integrated strategy of treatment monitoring outside the stringent frame of controlled clinical trials, based on relevant patient characteristics, clinical factors, potential drug-drug interactions, and measurement of circulating blood concentrations. So far, 91 blood samples from 46 PLWH have been collected. Most individuals are less than 50 years old, with relatively few comorbidities and comedications. The observed concentrations are globally in accordance with the available values reported in the randomized clinical trials. Yet, low RPV concentrations not exceeding twice the reported protein-adjusted 90% inhibitory concentration have been observed. Data available at present confirm a considerable between-patient variability overall. Based on the growing amount of PK data accumulated during this ongoing study, population pharmacokinetic analysis will characterize individual concentration-time profiles of LAI-CAB/RPV along with their variability in a real-life setting and their association with treatment response and tolerability, thus bringing key data for therapeutic monitoring and precision dosage adjustment of this novel long-acting therapy. MDPI 2022-07-29 /pmc/articles/PMC9413113/ /pubmed/36015214 http://dx.doi.org/10.3390/pharmaceutics14081588 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thoueille, Paul Alves Saldanha, Susana Schaller, Fabian Munting, Aline Cavassini, Matthias Braun, Dominique Günthard, Huldrych F. Kusejko, Katharina Surial, Bernard Furrer, Hansjakob Rauch, Andri Ustero, Pilar Calmy, Alexandra Stoeckle, Marcel Battegay, Manuel Marzolini, Catia Andre, Pascal Guidi, Monia Buclin, Thierry Decosterd, Laurent A. Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland |
title | Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland |
title_full | Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland |
title_fullStr | Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland |
title_full_unstemmed | Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland |
title_short | Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland |
title_sort | real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in switzerland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413113/ https://www.ncbi.nlm.nih.gov/pubmed/36015214 http://dx.doi.org/10.3390/pharmaceutics14081588 |
work_keys_str_mv | AT thoueillepaul reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT alvessaldanhasusana reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT schallerfabian reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT muntingaline reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT cavassinimatthias reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT braundominique reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT gunthardhuldrychf reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT kusejkokatharina reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT surialbernard reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT furrerhansjakob reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT rauchandri reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT usteropilar reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT calmyalexandra reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT stoecklemarcel reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT battegaymanuel reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT marzolinicatia reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT andrepascal reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT guidimonia reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT buclinthierry reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT decosterdlaurenta reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland AT reallifetherapeuticconcentrationmonitoringoflongactingcabotegravirandrilpivirinepreliminaryresultsofanongoingprospectiveobservationalstudyinswitzerland |